Clinical Edge Journal Scan

Ductal carcinoma in situ increases risk of dying from breast cancer by threefold

Publish date: October 8, 2020

Clinical Edge Breast Cancer: October 2020 (3 of 7)


 

Key clinical point: Women with ductal carcinoma in situ (DCIS) had a 3-fold increased risk of dying from breast cancer than women without DCIS.

Major finding: Among the cohort, 1,540 women with DCIS died of breast cancer. The expected number of deaths from breast cancer in the cancer-free cohort was 458.

Study details: Cohort study of 144,524 women diagnosed with DCIS from 1995 to 2014.

Disclosures: The authors report no conflicts of interest.

Source: Giannakeas, V, et al. JAMA Netw Open. 2020;3(9):e2017124. doi:10.1001/jamanetworkopen.2020.17124

Recommended Reading

Global stomach cancer deaths decline as colorectal cancer deaths stagnate, rise
MDedge Hematology and Oncology
Divergent findings with paclitaxel and nab-paclitaxel in TNBC
MDedge Hematology and Oncology
Cancer disparities: One of the most pressing public health issues
MDedge Hematology and Oncology
The scope of under- and overtreatment in older adults with cancer
MDedge Hematology and Oncology
Radiotherapy planning scans reveal breast cancer patients’ CVD risk
MDedge Hematology and Oncology
Restarting breast cancer screening after disruption not so simple
MDedge Hematology and Oncology
AI algorithm on par with radiologists as mammogram reader
MDedge Hematology and Oncology
Study supports multigene panel testing for all breast cancer patients with second primary cancers
MDedge Hematology and Oncology
Beyond baseline, DBT no better than mammography for dense breasts
MDedge Hematology and Oncology
Women 70 and older are divided on age-based guidelines for breast cancer treatment
MDedge Hematology and Oncology

Clinical Edge Breast Cancer: October 2020 (3 of 7)